LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. It effectively blocks the interaction between SDF-1 and CXCR4, as well as SDF-1-induced GTP binding. LY-2624587 significantly inhibits cellular migration and induces apoptosis in human lymphoma and leukemia cells. Additionally, LY-2624587 suppresses cell signaling mediated by CXCR4 and SDF-1, including MAPK and AKT activation. This compound is utilized in research on human hematological malignancies, such as acute myeloid leukemia (AML).